PEPG trades 47.1% below Wall Street's consensus target of $4.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes PEPG achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, PepGen Inc. (PEPG) has a Wall Street consensus price target of $4.00, based on estimates from 6 covering analysts. With the stock currently trading at $2.72, this represents a potential upside of +47.1%. The company has a market capitalization of $188M.
Analyst price targets range from a low of $4.00 to a high of $4.00, representing a 0% spread in expectations. The median target of $4.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, PEPG trades at a trailing P/E of -1.3x. Analysts expect EPS to grow -2.1% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 SRPTSarepta Therapeutics, Inc. | $2.0B | $18.95 | $23.33 | +23.1% | Buy | 5.7x | 55 |
 FOLDAmicus Therapeutics, Inc. | $4.5B | $14.49 | $14.86 | +2.6% | Buy | 40.6x | 24 |
 RAREUltragenyx Pharmaceutical Inc. | $1.5B | $14.88 | $25.83 | +73.6% | Buy | — | 33 |
 CRSPCRISPR Therapeutics AG | $5.4B | $55.76 | $67.83 | +21.6% | Buy | — | 38 |
 EDITEditas Medicine, Inc. | $413M | $2.69 | $4.00 | +48.7% | Buy | — | 25 |
 NTLAIntellia Therapeutics, Inc. | $1.4B | $12.33 | $23.00 | +86.5% | Buy | — | 39 |
 IONSIonis Pharmaceuticals, Inc. | $7.3B | $43.93 | $86.25 | +96.3% | Buy | — | 33 |
 ALNYAlnylam Pharmaceuticals, Inc. | $32.9B | $246.51 | $347.33 | +40.9% | Buy | 36.9x | 52 |
 ARWRArrowhead Pharmaceuticals, Inc. | $9.4B | $66.96 | $104.43 | +56.0% | Buy | — | 22 |
 WAVEEco Wave Power Global AB (publ) | $34M | $5.75 | — | — | — | — | — |
Quick answers to the most common questions about buying PEPG stock.
The consensus Wall Street price target for PEPG is $4, representing 47.1% upside from the current price of $2.72. With 6 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
PEPG has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $4 implies 47.1% upside from current levels.
PEPG's current price is $2.72 with a consensus target of $4 (47.1% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $4 for PEPG, while the most conservative target is $4. The consensus of $4 represents the median expectation. These targets typically reflect 12-month expectations.
PEPG is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 0 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month PEPG stock forecast based on 6 Wall Street analysts shows a consensus price target of $4, with estimates ranging from $4 (bear case) to $4 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on PEPG, with a "Buy" consensus rating and $4 price target (47.1% upside). 5 of 6 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
PEPG analyst price targets range from $4 to $4, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $4 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.